Illumina, Inc. (NASDAQ:ILMN) Receives $165.95 Consensus PT from Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given an average rating of “Moderate Buy” by the twenty ratings firms that are currently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $165.95.

A number of research firms have recently commented on ILMN. JPMorgan Chase & Co. boosted their price target on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Stephens upped their target price on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Canaccord Genuity Group lifted their price target on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. Morgan Stanley reissued an “equal weight” rating and set a $156.00 price objective on shares of Illumina in a report on Tuesday, November 12th. Finally, Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research note on Thursday, October 17th.

Illumina Stock Performance

NASDAQ:ILMN opened at $133.63 on Thursday. The business’s fifty day moving average is $142.19 and its 200 day moving average is $131.04. The firm has a market cap of $21.19 billion, a price-to-earnings ratio of -13.42 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina has a 52-week low of $100.08 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.33 earnings per share. Research analysts predict that Illumina will post 4.11 EPS for the current year.

Institutional Trading of Illumina

Several hedge funds and other institutional investors have recently bought and sold shares of ILMN. Primecap Management Co. CA grew its holdings in shares of Illumina by 462.5% in the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after purchasing an additional 1,997,010 shares during the last quarter. Millennium Management LLC boosted its position in Illumina by 305.0% during the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after buying an additional 1,118,747 shares during the period. Marshall Wace LLP bought a new stake in Illumina in the 2nd quarter worth $77,628,000. Massachusetts Financial Services Co. MA increased its position in shares of Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after acquiring an additional 631,294 shares during the period. Finally, Janus Henderson Group PLC raised its stake in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.